응용약물학회
사용자 메뉴
로그인
회원가입
ENGLISH
학술행사
학술대회
워크샵
후원사
유관기관 행사일정
교육프로그램
교육프로그램
온라인 교육원
학회지
Biomolecules & Therapeutics
E-Submission
K-Pharma
신약개발 사례
신약개발 벤처기업
학회소식
공지사항
학회력
행사일정
뉴스레터
갤러리
학회소개
인사말
역대 회장
임원진
연혁
정관
학술상
사무국
전시 및 후원
광고
후원 및 협찬
기부
회원공간
자유게시판
회원동정
구인구직
관련사이트
사용자 메뉴
로그인
회원가입
ENGLISH
학술행사
학술대회
워크샵
후원사
유관기관 행사일정
교육프로그램
교육프로그램
온라인 교육원
학회지
Biomolecules & Therapeutics
E-Submission
K-Pharma
신약개발 사례
신약개발 벤처기업
학회소식
공지사항
학회력
행사일정
뉴스레터
갤러리
학회소개
인사말
역대 회장
임원진
연혁
정관
학술상
사무국
전시 및 후원
광고
후원 및 협찬
기부
회원공간
자유게시판
회원동정
구인구직
관련사이트
K-Pharma
메인으로 바로가기
K-Pharma
학술행사
교육프로그램
학회지
K-Pharma
학회소식
학회소개
전시 및 후원
회원공간
신약개발 사례
신약개발 사례
신약개발 벤처기업
신약개발 사례
*
표시는 필수입력 사항으로 글 작성시 반드시 기재해야 하는 항목입니다.
작성자 *
이메일
비밀번호 *
* 글 수정 삭제시 필요하시 꼭 기재해 주시기 바랍니다.
제목 *
HTML사용
비밀글
<p class="0" style="margin-left:5.0pt;margin-right:5.0pt;text-align:center;word-break:keep-all;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;font-weight:bold;"><span lang="EN-US" style="letter-spacing: 0pt;"><br></span></span></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;text-align:center;word-break:keep-all;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;font-weight:bold;"><span lang="EN-US" style="letter-spacing: 0pt;"><br></span></span></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;text-align:center;word-break:keep-all;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;font-weight:bold;"><span lang="EN-US" style="letter-spacing: 0pt;">[</span><span style="font-family: 돋움, Dotum, Helvetica, sans-serif;">대웅제약</span><span lang="EN-US" style="letter-spacing: 0pt;">] </span><span style="font-family: 돋움, Dotum, Helvetica, sans-serif;">엔블로정 </span> </span></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;text-align:center;word-break:keep-all;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"><br></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"> <!--[if !supportEmptyParas]--> <!--[endif]--> <o:p></o:p></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"><span style="mso-fareast-font-family:Noto Sans KR;font-weight:bold;">허가 일자</span><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;font-weight:bold;">: 2022</span><span style="mso-fareast-font-family:Noto Sans KR;font-weight:bold;">년 </span><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;font-weight:bold;">11</span><span style="mso-fareast-font-family:Noto Sans KR;font-weight:bold;">월 </span><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;font-weight:bold;">30</span><span style="mso-fareast-font-family:Noto Sans KR;font-weight:bold;">일</span></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"> <!--[if !supportEmptyParas]--> <!--[endif]--> <o:p></o:p></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"><span style="mso-fareast-font-family:Noto Sans KR;font-weight:bold;">약리작용 및 기전</span></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;">엔블로정은 신장에서 포도당의 재흡수에 관여하는 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">SGLT-2(sodium glucose cotransporter 2, </span>나트륨<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">-</span>포도당 공동수송체<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">)</span>을 선택적으로 억제해 소변으로 배출되는 포도당의 혈류 내 재흡수를 차단하는 기전을 통해 혈당을 낮춘다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>제<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2</span>형 당뇨병 환자의 혈당 조절을 향상시키기 위해 식사용법 및 운동요법의 보조제로 사용된다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>신장 근위세뇨관의 포도당 재흡수에 관여하는 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">SGLT</span>는 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">1</span>형과 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2</span>형의 두가지 아형이 존재하는데 이 중 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">SGLT-2</span>가 약 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">90% </span>가량의 포도당 재흡수에 관여하는 것으로 알려져 있다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>일반적으로 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">SGLT-2 </span>억제제는 심혈관 및 뇌혈관 합병증 등의 발생을 억제할 수 있는 것으로 알려지고 있다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">.</span></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"> <!--[if !supportEmptyParas]--> <!--[endif]--> <o:p></o:p></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"><span style="mso-fareast-font-family:Noto Sans KR;font-weight:bold;">연구개발 과정 및 최종 결과</span></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;">엔블로정은 대웅제약이 순수 국산 기술로 개발로 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2016</span>년 개발을 시작해 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2022</span>년 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">11</span>월 식품의약품안전처<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">(</span>식약처<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">) </span>품목허가를 획득한 국산 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">36</span>호 신약이다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>엔블로정은 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2020</span>년 식약처의 신속심사대상 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">1</span>호 의약품으로 지정돼 수시동반심사 제도를 활용해 허가 관련 심사가 빠르게 진행된 신약으로<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>적응증은 단독요법<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>메트포르민 병용요법<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>메트포르민과 제미글립틴 병용요법 총<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">3</span>건이다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>단독요법 시험은 위약 대비 당화혈색소<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">(HbA1c)</span>가 약 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">1%p </span>감소해 통계적으로 유의성을 확보했고<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>체중<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>혈압<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>저밀도지질단백질<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">-</span>콜레스테롤<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">(LDL-C), </span>고밀도지질단백질<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">-</span>콜레스테롤<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">(HDL-C)</span>에서도 위약 대비 유의한 개선을 확인했다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>메트포르민 병용 시험에서는 활성 대조약인 다파글리플로진 대비 당화혈색소 변화율에서 비열등함을 입증하는 동시에 인슐린저항성<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">(HOMA-IR)</span>에서 유의적인 개선을 확인했다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>또한 안전성 측면에서 유의적으로 낮은 약물 이상반응을 확인해 안전성과 내약성을 입증했다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>메트포르민과 제미글립틴 병용시험 역시 활성 대조약인 다파글리플로진 대비 당화혈색소 변화율에서 비열등함을 입증했다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">.</span>엔블로정은 기존 출시된 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">SGLT-2 </span>억제제의 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">30</span>분의 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">1 </span>이하에 불과한 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">0.3mg</span>만으로 동등 이상의 약효를 보였으며<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>제<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2</span>형 당뇨병 환자를 대상으로 진행한 임상 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">3</span>상을 통해 기존 시판약물 대비 뛰어난 당화혈색소<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">(HbA1c)·</span>공복혈당 강하효과 및 안전성이 입증되어 기존의 치료제로 혈당 조절이 불충분했던 환자들에게 새로운 치료 옵션이 될 것으로 기대되고 있다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>엔블로정이 적은 용량으로 동일 계열 약물과 대등한 혈당 강하 효과를 보이는 것은 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">SGLT-2</span>와 강하게 결합하고<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>요당 배출량이 상대적으로 높았다는 점 등이 작용한 것으로 보고되었고<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>한국인을 대상으로 풍부한 임상 데이터를 확보했다는 점도 강점으로 평가되었다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>또한 엔블로정은 허가임상연구에서 체중감소<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>혈압감소<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">,·</span>지질 프로파일 개선 및<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">·</span>인슐린 저항성 개선 효과를 보였고<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>신장 기능이 저하된 제<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2</span>형 당뇨병 환자에서 동일 계열 약물 대비 우수한 혈당 강하효과 및 단백뇨 개선효과를 확인했다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>따라서 엔볼로정은 당뇨<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>대사질환<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>심부전<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>신부전을 통합 치료할 수 있는 치료제로 알려지면서 다른 질환 분야에서도 성장 가능성이 높을 것으로 평가받고 있다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">.</span>엔블로정과 메트포르민 복합제인 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">'</span>엔블로멧서방정<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">0.3/1000</span>밀리그램<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">'</span>은 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2023</span>년 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">6</span>월 식약처의 허가를 받았고 하반기 출시될 예정이다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span>또한 최근 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">3</span>제 이상 당뇨병 치료제 병용요법이 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">5</span>년 새 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">38%</span>로 증가 추세임을 고려하여<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">, </span>대웅제약은 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">2023</span>년 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">4</span>월 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">SGLT-2 </span>억제제 병용 급여 확대에 따른 시장 대응을 위해 엔블로<span style="mso-fareast-font-family:Noto Sans KR;mso-hansi-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">∙</span>제미글립틴<span style="mso-fareast-font-family:Noto Sans KR;mso-hansi-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">∙</span>메트포르민 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">3</span>제 병용 장기 <span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">3</span>상 임상시험을 신청한 바 있다<span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">. </span></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"> <!--[if !supportEmptyParas]--> <!--[endif]--> <o:p></o:p></p><p class="0" style="margin-left:5.0pt;margin-right:5.0pt;mso-pagination:none;text-autospace:none;mso-padding-alt:0.0pt 0.0pt 0.0pt 0.0pt;"> <!--[if !supportEmptyParas]--> <!--[endif]--> <o:p></o:p></p><p class="0" style="margin-left: 5pt; margin-right: 5pt; word-break: keep-all;"><span style="mso-fareast-font-family:Noto Sans KR;font-weight:bold;">홈페이지</span><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;font-weight:bold;">: </span><a href="https://m.daewoong.co.kr/kr/product/product-detail?pageIndex=1&srchfld=detail?pageIndex=pageIndex=1&srchfld=a&srchkey=&srchcho=&srchcls2=&seltab=&idx=453&srchword=&srchcls=&srcheff"><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;">https://m.daewoong.co.kr/kr/product/product-detail?pageIndex=1&srchfld=detail?pageIndex=pageIndex=1&srchfld=a&srchkey=&srchcho=&srchcls2=&seltab=&idx=453&srchword=&srchcls=&srcheff</span></a></p><p class="0" style="margin-left: 5pt; margin-right: 5pt; word-break: keep-all;"> <!--[if !supportEmptyParas]--> <!--[endif]--> <o:p></o:p></p><p class="0" style="margin-left: 5pt; margin-right: 5pt; word-break: keep-all;"><span style="mso-fareast-font-family:Noto Sans KR;font-weight:bold;">정보출처</span><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;font-weight:bold;">: </span><span lang="EN-US" style="font-family:Noto Sans KR;mso-ascii-font-family:Noto Sans KR;mso-font-width:100%;letter-spacing:0.0pt;mso-text-raise:0.0pt;"><a href="https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202204314aupdateTs2023-09-01%2000:41:25.847652b">https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=202204314aupdateTs2023-09-01%2000:41:25.847652b</a></span></p> ==================== 답 변 ====================
첨부파일1
자동등록방지
* 왼쪽의 자동등록방지 코드를 입력하세요.
리스트
확인
취소
주무관청
후원사
